JP2015214582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015214582A5 JP2015214582A5 JP2015160099A JP2015160099A JP2015214582A5 JP 2015214582 A5 JP2015214582 A5 JP 2015214582A5 JP 2015160099 A JP2015160099 A JP 2015160099A JP 2015160099 A JP2015160099 A JP 2015160099A JP 2015214582 A5 JP2015214582 A5 JP 2015214582A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- antibody
- treatment
- her2 antibody
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims 5
- 206010027476 Metastases Diseases 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 238000009097 single-agent therapy Methods 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06017330.9 | 2006-08-21 | ||
| EP06017330 | 2006-08-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013103182A Division JP2013163687A (ja) | 2006-08-21 | 2013-05-15 | 抗ｖｅｇｆ抗体による腫瘍治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015214582A JP2015214582A (ja) | 2015-12-03 |
| JP2015214582A5 true JP2015214582A5 (https=) | 2017-08-31 |
Family
ID=37607207
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524943A Pending JP2010501498A (ja) | 2006-08-21 | 2007-08-17 | 抗ｖｅｇｆ抗体による腫瘍治療 |
| JP2013103182A Withdrawn JP2013163687A (ja) | 2006-08-21 | 2013-05-15 | 抗ｖｅｇｆ抗体による腫瘍治療 |
| JP2015160099A Ceased JP2015214582A (ja) | 2006-08-21 | 2015-08-14 | 抗ｖｅｇｆ抗体による腫瘍治療 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524943A Pending JP2010501498A (ja) | 2006-08-21 | 2007-08-17 | 抗ｖｅｇｆ抗体による腫瘍治療 |
| JP2013103182A Withdrawn JP2013163687A (ja) | 2006-08-21 | 2013-05-15 | 抗ｖｅｇｆ抗体による腫瘍治療 |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US20080050385A1 (https=) |
| EP (2) | EP2441472B1 (https=) |
| JP (3) | JP2010501498A (https=) |
| KR (1) | KR101136763B1 (https=) |
| CN (1) | CN101505792B (https=) |
| AR (1) | AR062419A1 (https=) |
| AU (1) | AU2007287794B2 (https=) |
| BR (1) | BRPI0715829A2 (https=) |
| CA (1) | CA2660681A1 (https=) |
| CL (1) | CL2007002404A1 (https=) |
| CO (1) | CO6150193A2 (https=) |
| CR (1) | CR10590A (https=) |
| DK (1) | DK2056874T3 (https=) |
| ES (2) | ES2546066T3 (https=) |
| IL (2) | IL196810A0 (https=) |
| MA (1) | MA30654B1 (https=) |
| MX (1) | MX2009001715A (https=) |
| MY (1) | MY150756A (https=) |
| NO (1) | NO20090450L (https=) |
| NZ (1) | NZ574580A (https=) |
| PE (1) | PE20080911A1 (https=) |
| PL (1) | PL2056874T3 (https=) |
| RU (1) | RU2528884C2 (https=) |
| SG (1) | SG174090A1 (https=) |
| SI (1) | SI2056874T1 (https=) |
| TW (2) | TW200825106A (https=) |
| WO (1) | WO2008022746A1 (https=) |
| ZA (1) | ZA200901200B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130056201A (ko) * | 2000-05-19 | 2013-05-29 | 제넨테크, 인크. | ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
| KR20140032004A (ko) | 2004-07-22 | 2014-03-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2008523073A (ja) * | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Ｈｅｒ阻害剤を用いた治療のための患者の選択 |
| CA2592177A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| DK2056874T3 (da) * | 2006-08-21 | 2012-10-15 | Hoffmann La Roche | Tumorterapi med et anti-vegf-antistof |
| MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| CN114805583A (zh) | 2010-05-27 | 2022-07-29 | 根马布股份公司 | 针对her2的单克隆抗体 |
| JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー／エス | Ｈｅｒ２エピトープに対するモノクローナル抗体 |
| JP5963005B2 (ja) * | 2010-07-19 | 2016-08-03 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー |
| NZ607337A (en) * | 2010-08-20 | 2015-06-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| CA2832389A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| WO2013055874A2 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| KR20140094594A (ko) * | 2011-12-05 | 2014-07-30 | 에프. 호프만-라 로슈 아게 | 유방암 치료를 위한 베바시주맙 병용 치료에 대한 혈장 바이오마커 |
| WO2013148159A1 (en) * | 2012-03-30 | 2013-10-03 | Fibrogen Inc | Therapeutic methods for peritoneal carcinomatosis |
| RU2019115089A (ru) | 2013-04-16 | 2019-06-11 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| JP2017513901A (ja) | 2014-04-25 | 2017-06-01 | ジェネンテック， インコーポレイテッド | トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法 |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| US11406715B2 (en) | 2015-05-30 | 2022-08-09 | Genentech, Inc. | Methods of treating HER2-positive metastatic breast cancer |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| TWI734775B (zh) * | 2016-04-26 | 2021-08-01 | 美商美國泰福生技股份有限公司 | 細胞培養基 |
| AU2017387909A1 (en) | 2016-12-28 | 2019-06-27 | Genentech, Inc. | Treatment of advanced HER2 expressing cancer |
| SG11201905622VA (en) | 2017-01-17 | 2019-08-27 | Genentech Inc | Subcutaneous her2 antibody formulations |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
| AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
| US20230330094A1 (en) * | 2020-09-04 | 2023-10-19 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Combination compositions and methods for treating cancer |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| BR9207175A (pt) | 1992-10-28 | 1995-12-12 | Genentech Inc | Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero |
| US6071935A (en) | 1996-06-27 | 2000-06-06 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
| CN101412758A (zh) | 1996-10-18 | 2009-04-22 | 基因技术股份有限公司 | 抗ErbB2抗体 |
| JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| EP2338915A3 (en) | 1997-04-07 | 2011-10-12 | Genentech, Inc. | Anti-VEGF antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| JPH11236333A (ja) | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−４−オン誘導体 |
| KR20010071271A (ko) | 1998-05-15 | 2001-07-28 | 존 비. 랜디스 | 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법 |
| TR200101343T2 (tr) | 1998-08-27 | 2001-09-21 | Pfizer Products Inc. | Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri |
| DE69923849T2 (de) | 1998-08-27 | 2006-01-12 | Pfizer Products Inc., Groton | Quinolin-2-on-derivate verwendbar als antikrebsmittel |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
| WO2000035956A1 (fr) | 1998-12-16 | 2000-06-22 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps monoclonal anti-vegf humain |
| SK11002001A3 (sk) | 1999-02-11 | 2002-05-09 | Pfizer Products Inc. | Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky |
| US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
| JP5623681B2 (ja) | 1999-05-14 | 2014-11-12 | ジェネンテック， インコーポレイテッド | 抗−ＥｒｂＢ２抗体による治療 |
| US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| IL147017A0 (en) | 1999-06-25 | 2002-08-14 | Genentech Inc | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
| CA2376596C (en) | 1999-06-25 | 2009-10-06 | Genentech, Inc. | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
| PT1106612E (pt) | 1999-11-30 | 2004-06-30 | Pfizer Prod Inc | Derivados de quinolina uteis para inibir a farnesil-proteina-transferase |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
| WO2003042402A2 (en) * | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| US20060036086A1 (en) | 2002-03-12 | 2006-02-16 | Jain Rakesh K | Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases |
| US7435797B2 (en) | 2002-04-10 | 2008-10-14 | Genentech, Inc. | Anti-HER2 antibody variants |
| US20040243207A1 (en) | 2003-05-30 | 2004-12-02 | Olson Donald R. | Medical implant systems |
| MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| CA2534055A1 (en) | 2003-08-01 | 2005-02-10 | Genentech, Inc. | Antibody cdr polypeptide sequences with restricted diversity |
| KR100956913B1 (ko) | 2003-12-19 | 2010-05-11 | 제넨테크, 인크. | 치료제로서 유용한 일가 항체 단편 |
| EP1789446A2 (en) * | 2004-09-02 | 2007-05-30 | Genentech, Inc. | Heteromultimeric molecules |
| BRPI0515670A (pt) * | 2004-10-04 | 2008-07-29 | Genentech Inc | anticorpos isolados e método de tratamento de uma doença associada com descontrole da sinalização do hgf/c-met |
| CN101355965A (zh) * | 2005-06-08 | 2009-01-28 | 达纳－法伯癌症研究院 | 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物 |
| TW200812615A (en) * | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| DK2056874T3 (da) * | 2006-08-21 | 2012-10-15 | Hoffmann La Roche | Tumorterapi med et anti-vegf-antistof |
| JP2013103182A (ja) * | 2011-11-15 | 2013-05-30 | Toray Ind Inc | スパイラル型流体分離素子およびその製造方法 |
-
2007
- 2007-08-17 DK DK07786693.7T patent/DK2056874T3/da active
- 2007-08-17 MX MX2009001715A patent/MX2009001715A/es active IP Right Grant
- 2007-08-17 CA CA002660681A patent/CA2660681A1/en not_active Abandoned
- 2007-08-17 MY MYPI20090667 patent/MY150756A/en unknown
- 2007-08-17 US US11/840,279 patent/US20080050385A1/en not_active Abandoned
- 2007-08-17 SG SG2011060142A patent/SG174090A1/en unknown
- 2007-08-17 AU AU2007287794A patent/AU2007287794B2/en not_active Ceased
- 2007-08-17 NZ NZ574580A patent/NZ574580A/en not_active IP Right Cessation
- 2007-08-17 CN CN2007800308557A patent/CN101505792B/zh not_active Expired - Fee Related
- 2007-08-17 ES ES11193793.4T patent/ES2546066T3/es active Active
- 2007-08-17 RU RU2009110102/15A patent/RU2528884C2/ru not_active IP Right Cessation
- 2007-08-17 SI SI200731075T patent/SI2056874T1/sl unknown
- 2007-08-17 EP EP11193793.4A patent/EP2441472B1/en not_active Revoked
- 2007-08-17 KR KR1020097003557A patent/KR101136763B1/ko not_active Expired - Fee Related
- 2007-08-17 EP EP07786693A patent/EP2056874B1/en not_active Revoked
- 2007-08-17 CL CL200702404A patent/CL2007002404A1/es unknown
- 2007-08-17 ES ES07786693T patent/ES2392630T3/es active Active
- 2007-08-17 AR ARP070103667A patent/AR062419A1/es unknown
- 2007-08-17 JP JP2009524943A patent/JP2010501498A/ja active Pending
- 2007-08-17 PL PL07786693T patent/PL2056874T3/pl unknown
- 2007-08-17 WO PCT/EP2007/007276 patent/WO2008022746A1/en not_active Ceased
- 2007-08-17 BR BRPI0715829-7A2A patent/BRPI0715829A2/pt not_active Application Discontinuation
- 2007-08-20 TW TW096130765A patent/TW200825106A/zh unknown
- 2007-08-20 TW TW099141756A patent/TW201107346A/zh unknown
- 2007-08-20 PE PE2007001129A patent/PE20080911A1/es not_active Application Discontinuation
-
2009
- 2009-01-29 CR CR10590A patent/CR10590A/es not_active Application Discontinuation
- 2009-01-29 IL IL196810A patent/IL196810A0/en unknown
- 2009-01-29 NO NO20090450A patent/NO20090450L/no not_active Application Discontinuation
- 2009-02-19 ZA ZA2009/01200A patent/ZA200901200B/en unknown
- 2009-02-19 MA MA31650A patent/MA30654B1/fr unknown
- 2009-02-24 CO CO09018558A patent/CO6150193A2/es unknown
-
2010
- 2010-05-20 US US12/784,309 patent/US20100285010A1/en not_active Abandoned
-
2011
- 2011-05-19 US US13/111,784 patent/US20110223159A1/en not_active Abandoned
-
2012
- 2012-08-14 US US13/585,095 patent/US20130183292A1/en not_active Abandoned
-
2013
- 2013-05-15 JP JP2013103182A patent/JP2013163687A/ja not_active Withdrawn
-
2015
- 2015-03-30 IL IL238045A patent/IL238045A0/en unknown
- 2015-05-13 US US14/711,671 patent/US20150239969A1/en not_active Abandoned
- 2015-08-14 JP JP2015160099A patent/JP2015214582A/ja not_active Ceased
-
2017
- 2017-10-23 US US15/791,285 patent/US20180251536A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015214582A5 (https=) | ||
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| MX2018015353A (es) | Usos terapeuticos de un inhibidor de c-raf. | |
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| AR062840A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2) | |
| WO2018136412A3 (en) | Subcutaneous her2 antibody formulations | |
| MY208022A (en) | Anti-claudin 18.2 antibody and application thereof | |
| SG10201804945WA (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| JP2014509659A5 (https=) | ||
| MY205774A (en) | Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof | |
| EA033400B1 (ru) | Антитело против cd3 и его применение | |
| RU2017144185A (ru) | Терапевтические комбинации и способы лечения новообразований | |
| MY198928A (en) | B7-h3 antibody, antigen-binding fragment thereof and medical use thereof | |
| ZA202004701B (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| JP2019506403A5 (https=) | ||
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| JP2014512354A5 (https=) | ||
| JP2016520082A5 (https=) | ||
| MX2019014375A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. | |
| MY183712A (en) | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases | |
| JP2016515124A5 (https=) | ||
| MX2020010119A (es) | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. |